BRVE
Braveheart Bio, Inc.
BRVE
Closed
$21.98
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Braveheart Bio, Inc. is a US-based company operating in industry. The company is headquartered in San Francisco, California and currently employs 30 full-time employees. The company went IPO on 2026-08-06. Braveheart Bio, Inc. is a clinical stage biopharmaceutical company. The firm is focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Its lead product candidate, BHB 1893, is an oral small-molecule cardiac myosin inhibitor (CMI), that it is developing for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Its pipeline is focused on advancing BHB-1893 across multiple cardiovascular indications with significant unmet need. HCM is a chronic, progressive disease characterized by abnormal thickening and impaired relaxation of the heart.
Key stats
Open
$23.21
Volume
829.31K
Market cap
$2.13B
Prev. close
$23.61
Impl / hst vl
-
Open interest
$0.00
$21.90
Day’s Range
$23.76
$23.42
52W Range
$32.00
Valuation
33
Valuation score
Overvalued
P/E
-
P/S
-
P/B
-
Current ratio
-
Debt / Equity
-
ROE
-
Gross margin
-
Income growth
-78.38%
FCF growth
-
Analysts estimates
Avg. price target
$46.16
The top 6 analysts forecasts that 12-month price may increase by 109.99%, with a low of $40.40 and a high of $50.40
$40.40
Low
$46.16
Avg
$50.40
High
Current price
Earnings
Q1 ‘26 revenue
$0.00
Q1 ‘26 net income
-$14.28M
Revenue
Net income
Previous EPS
-Estimate EPS
$4.40
Actual EPS
Estimate EPS
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply